2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-19496
    4-Butyl-alpha-agarofuran 272126-07-5 ≥98.0%
    4-Butyl-alpha-agarofuran (AF 5) is an anxiolytic and antidepressant agent. 4-Butyl-alpha-agarofuran a α-agarofuran derivative that can be isolated from Gharu-wood. 4-Butyl-alpha-agarofuran can be used for the research of neurological disease research.
    4-Butyl-alpha-agarofuran
  • HY-19627
    Naldemedine 916072-89-4 98%
    Naldemedine (S-297995) is an orally active μ-opioid receptor antagonist (PAMORA). Naldemedine shows potent binding affinities (Ki=0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC50=25.57, 7.09, 16.1 nM, respectively) for recombinant human μ-, δ-, and κ- opioid receptors. Naldemedine can be used in opioid-induced constipation (OIC) research. Naldemedine is predicted to bind to 3CLpro encoded by SARS-CoV2 genome.
    Naldemedine
  • HY-19686
    Ipsapirone 95847-70-4
    Ipsapirone (TVX Q 7821) is an anxiolytic compound and a 5-HT1A receptor partial agonist. Ipsapirone (TVX Q 7821) also exhibits 5-HT1A receptor antagonistic effect, and only at high doses it can also produce an inhibitory effect on 5-HT2 and the α1-adrenergic function.
    Ipsapirone
  • HY-19849
    BGC-20-1531 free base 736183-35-0 98.05%
    BGC-20-1531 (PGN 1531) free base is a potent and selective prostanoid EP4 receptor antagonist, with a pKB of 7.6. BGC-20-1531 free base has the potential for the research of migraine headache.
    BGC-20-1531 free base
  • HY-19872
    AZD-6280 942436-93-3 99.09%
    AZD-6280 is a selective GABAA(α2/3) receptor modulator, used for treatment of generalized anxiety disorder.
    AZD-6280
  • HY-19978
    RO-3 1026582-88-6
    RO-3 is a potent, CNS-penetrant, and orally active P2X3 and P2X2/3 antagonist with pIC50s of 5.9 and 7.0 for human homomultimeric P2X3 and heteromultimeric P2X2/3 receptors, respectively. RO-3 shows selectivity for P2X3 and P2X2/3 over all other functional homomultimeric P2X receptors (IC50 >10?μM at P2X1,2,4,5,7).
    RO-3
  • HY-21297
    3,5-Dihydroxy-2-naphthoic acid 89-35-0 98%
    3,5-Dihydroxy-2-naphthoic acid is a Naphthoic acid derivative. Naphthoic acid is a NMDA receptor allosteric modulator.
    3,5-Dihydroxy-2-naphthoic acid
  • HY-30006
    1-Aminocyclobutanecarboxylic acid 22264-50-2 ≥98.0%
    1-Aminocyclobutanecarboxylic acid is a NMDA receptor partial agonist acting at the glycine site, NR1.
    1-Aminocyclobutanecarboxylic acid
  • HY-32854
    4-Bromo-3-(trifluoromethyl)aniline 393-36-2 ≥98.0%
    4-Bromo-3-(trifluoromethyl)aniline (5-Amino-2-bromobenzotrifluoride) can be used for synthesis of AUY954 (HY-119221) (a S1P1 receptor agonist).
    4-Bromo-3-(trifluoromethyl)aniline
  • HY-50754
    gamma-secretase modulator 2 1093978-89-2 98.80%
    gamma-secretase modulator 2 is a potent and selective γ-secretase modulator for study of Alzheimer's disease.
    gamma-secretase modulator 2
  • HY-50889
    gamma-secretase modulator 3 1431697-84-5 ≥98.0%
    gamma-secretase modulator 3 is a gamma-secretase modulator.
    gamma-secretase modulator 3
  • HY-A0118
    Naloxegol 854601-70-0 98%
    Naloxegol (NKTR-118; AZ-13337019) is a μ-opioid-receptor antagonist. Naloxegol inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation.
    Naloxegol
  • HY-A0125
    Alizapride 59338-93-1 98%
    Alizapride is a potent antiemetic, acting as a dopamine receptor antagonist. Alizapride also used in human digestive disorders.
    Alizapride
  • HY-A0160
    Indalpine 63758-79-2 98%
    Indalpine (LM 5008) is a potent and selective 5-HT uptake blocker. Indalpine is potent in displacing 3H-5-HT bound to brain membranes with the IC50 of 36 μM. Indalpine, two antidepressant agent.
    Indalpine
  • HY-A0198
    Adinazolam 37115-32-5 ≥99.0%
    Adinazolam (U 41123) is a triazolobenzodiazepine. Adinazolam binds to peripheral-type benzodiazepine receptors which interact allosterically with GABA receptors. Adinazolam has dual anxiolytic and antidepressant activities.
    Adinazolam
  • HY-B0197
    Naratriptan 121679-13-8 98%
    Naratriptan is an orally active and selective 5-HT1B/1D receptor agonist. Naratriptan is peripherally active and has good oral bioavailability, inducing cranial artery vasoconstriction by activating 5-HT1B/1D receptors (EC50=0.11 μM for dog basilar artery). Naratriptan also inhibits trigeminal nerve-mediated dural neurogenic plasma extravasation and reduces sterile inflammation. Naratriptan is mainly used in the research of acute migraine, targeting cranial vascular and neuroinflammatory mechanisms.
    Naratriptan
  • HY-B0884
    Minaprine 25905-77-5 98%
    Minaprine is a reversible inhibitor of MAO-A; weakly inhibit acetylcholinesterase; an antidepressant for treatment of depression.
    Minaprine
  • HY-B0954
    Oxyphencyclimine hydrochloride 125-52-0 99.61%
    A new tertiary amine, Oxyphencyclimine hydrochloride，has been investigated for its effects on the peripheral parasympathetic system.
    Oxyphencyclimine hydrochloride
  • HY-B1230
    Camylofine 54-30-8 98%
    Camylofin is an antimuscarinic, is a smooth muscle relaxant .
    Camylofine
  • HY-B1251
    Guanethidine 55-65-2 98%
    Guanethidine sulphate was synthesized in 1959. Guanethidine is thought to lowing blood pressure by interfering with the metabolism of chemical transmitter substances in post-ganglionic sympathetic nerve fibres.
    Guanethidine
Cat. No. Product Name / Synonyms Application Reactivity